Skip to content

    Cancer Clinical Trials

    A Phase 2 Trial of 61Cu-NU101 PET/​CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/​CT

    Learn more

    What is the purpose of this study?

    The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases. 34 participants with biopsy-proven prostate cancer and cancer seen on a Pylarify PET scan will be enrolled in this study. The investigational 61Cu-NU101 PET/CT will be perfromed. If there is a difference between the standard Pylarify exam and the investigational 61Cu-NU101 exam, a biopsy of one lesion that is different between the two exams may be performed.

    Eligibility

    1. Biopsy proven prostate adenocarcinoma
    2. Age ≥ 18 years
    3. ECOG 0 or 2 4 .Oligometastatic disease (1-5 radiotracer avid disease sites) on 18F- piflufolastat PET/CT within 30 days of trial recruitment

    Where can I participate?

    Hoag Hospital Irvine
    16200 Sand Canyon Ave
    Irvine, CA 92618


    Lauren Wagner

    lauren.wagner@hoag.org


    More about this Clinical Trial

    What is the full name of this Clinical Trial?

    A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer

    • Principal InvestigatorGary Ulaner, MD
    • Co-InvestigatorsRyan P. Reddy, MD, David Benjamin, MD
    • Age GroupAdult, Older Adult
    • PhaseII
    • ClinicalTrials.gov IDNCT07635524

    Stay up-to-date on the latest news from Hoag

    By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.